While this is a promising rebound, the outlook continues to remain uncertain as the world battles a more severe third wave of coronavirus, particularly in Nanosonics’ key geographies. Our forecast for fiscal 2021 revenue growth of 19% and EPS growth of 25% is unchanged, and we think early performance is tracking in line with our full-year expectations.
Shares continue to screen as overvalued, reflecting the market’s more optimistic view of Nanosonics’ new product in infection prevention, which remains undefined but is expected to begin commercialisation in fiscal 2022.
Despite improvements in hospital access for the company’s sales team, new trophon units installed still declined 9% pcp, with 19% growth in the EMEA segment but a 10% decline in North America. We view the differing growth rates as indicative of the company finding it increasingly difficult to sell additional units in North America where it’s enjoyed most of its success. New capital sales in North America contributed 87% of the total in fiscal 2020 but fell 18% and have fallen 13% on average over the last three years.
Total installed base growth rate to slow to 10% on average over the next three years, followed by lower growth once the device patent expires in 2025 and the more easily addressable markets are heavily penetrated. We maintain our five-year group revenue and EPS CAGR forecasts of 15% and 32%, respectively.
Our five-year revenue growth forecast reflects 17% CAGR in capital sales and 11% CAGR in consumables and service.
(Source: Morningstar)
Disclaimer
General Advice Warning
Any advice/ information provided is general in nature only and does not take into account the personal financial situation, objectives or needs of any particular person.